The proposed purchase of a portion of JB Chemicals and Pharmaceuticals by Torrent Pharmaceuticals Ltd. was approved by fair trade regulator CCI on 21 October, contingent on voluntary changes made by the parties. The move followed Torrent Pharmaceuticals’ announcement in June of this year that it would pay INR 19,500 crore to acquire the bulk of JB Chemicals and Pharmaceuticals.
In a statement, the regulator stated that the proposed combination is related to the acquisition of shares in JB Chemicals & Pharmaceuticals Ltd (target) by Torrent Pharmaceuticals Ltd (acquirer) and the subsequent merger of the target and the acquirer. Torrent Pharmaceuticals would be the second-most valuable pharmaceutical business in India if the deal is finalised.
Second Largest Deal in India’s Pharma Sector
Following Sun Pharmaceutical Industries’ 2015 acquisition of Ranbaxy Laboratories, this will be the second-biggest deal in the pharmaceutical industry history. JB Pharma will combine with Torrent following the acquisition of shares. For roughly INR 11,917 crore, Torrent announced in June that it would buy a 46.39% interest from promoters Tau Investment Holdings Pte Ltd, a division of the international investment group KKR.
Additionally, it would pay about INR 719 crore to purchase an additional 2.80% from specific JB Chemicals employees. Following this, it would make an open offer to purchase a 26% interest for INR 6,842.8 crore in accordance with Sebi’s listing requirements. The primary business of the Torrent group, Torrent Pharmaceuticals, manufactures and markets pharmaceutical formulations (FDFs) for a variety of therapeutic areas. In addition to producing and selling a wide variety of FDFs and active pharmaceutical ingredients (APIs), JB Chemicals and Pharmaceuticals also offers contract development and manufacturing organisation (CDMO) services.
In a post on X, the competition watchdog stated that the commission has approved Torrent Pharmaceuticals Ltd.’s acquisition of JB Chemicals & Pharmaceuticals Ltd. with voluntary changes. The Commission approved the proposed merger, the regulator added, provided that the parties (Torrent Pharmaceuticals Ltd. and JB Chemicals & Pharmaceuticals Ltd.) complied with the voluntary changes they presented.
Financial Dynamics of Torrent Pharma & JB Chemicals & Pharmaceuticals
KKR acquired a 65% share in JB Chemicals & Pharmaceuticals in 2020. Through open market transactions, KKR sold a 5.8% share in JB Pharma in March of this year for INR 1,460 crore. The cornerstone business of the Torrent Group, which generates INR 45,000 crore in total revenue annually, is Torrent Pharma, which generates around INR 11,500 crore. In an all-stock deal valued at USD 4 billion, including USD 800 million in debt, Sun Pharma announced in April 2014 that it will buy ailing rival Ranbaxy.
A year later, in March 2015, the merger was “consummated” once the necessary permissions were obtained. The acquisition of Bharat Serums and Vaccines by Mankind Pharma last year for INR 13,768 crore was another significant deal. In a different announcement, CCI authorised Setu AIF Trust, Konark Trust, and MMPL Trust to purchase a portion of Edelweiss Asset Management Ltd and Edelweiss Trusteeship Company Ltd.
According to the watchdog, Setu AIF Trust, Konark Trust, and MMPL Trust will acquire up to 15% of the shares in Edelweiss Asset Management Ltd (EAML) and Edelweiss Trusteeship Company Ltd (ETCL) as a result of the proposed combination’s interrelated processes. Setu AIF Trust is an alternative investment fund (AIF) that is registered with SEBI. Through MMPL, its investment manager, it takes action. ETCL serves as the trustee for Edelweiss Mutual Fund (EMF), while EAML manages the fund’s assets.
Quick Shots
•CCI
approves Torrent Pharmaceuticals’ acquisition of a stake in JB Chemicals
& Pharmaceuticals on 21 October 2025.
•Total
deal expected to cost INR 19,500 crore, making it the second-largest pharma
deal in India after Sun Pharma-Ranbaxy.
•After
acquisition, Torrent Pharma becomes the second-most valuable pharmaceutical
company in India.
On 12 September, the National Pharmaceutical Pricing Authority (NPPA) ordered all producers of pharmaceuticals and medical devices to lower their goods’ maximum retail prices (MRPs) right away.
The government’s decision to rationalise the goods and services tax (GST) rates on medications and formulations, which was recommended at the 56th meeting of the GST Council, prompted this action. The goal of the NPPA’s move, which goes into effect on September 22, is to guarantee that the public directly benefits from the GST cut.
On September 12, the NPPA issued a formal memorandum outlining precise guidelines for the pharmaceutical sector. It stated that in order to comply with the new GST rates, all manufacturers and marketing firms must update the maximum retail price of their medications and medical equipment.
Till Now, No Penalties for Non-Compliance
Although the NPPA statement does not outline sanctions for non-compliance, it does have the power to keep an eye on medication and medical device costs and to take corrective action if necessary. Under the Essential Commodities Act of 1955, failure to comply with NPPA’s price notifications may result in prosecution, which carries penalties such as fines and jail.
Manufacturers must provide dealers, merchants, state drug controllers, and the government with an updated or supplemental price list to guarantee a seamless implementation. The public finds the NPPA’s directive to be extremely important, according to a number of media sources.
The authority is making sure that the drop in the GST rate results in lower pricing for customers by requiring the modification of MRPs, which will make necessary medications and medical equipment more accessible and reasonably priced. Patients nationwide will profit from this judgement because it has a direct effect on their out-of-pocket medical costs.
Raising Awareness: How the Public will be Informed
In order to guarantee that the public is informed of these developments, the regulator has also underlined the necessity of extensive communication. Manufacturers and marketing firms are directed to notify dealers, retailers, and customers about the lower GST rates and the associated updated MRPs using all available means, such as print, electronic, and social media.
To guarantee compliance, industry associations have also been requested to place ads in both national and local media. For the stakeholders in the pharmaceutical business as well as the government, the choice is very important. By using fiscal policy to lessen the financial burden of healthcare on citizens, the government shows its dedication to consumer welfare and health fairness.
The NPPA has given the industry advice on how to handle the changeover. The memo makes it clear that if businesses can guarantee price compliance at the retail level, they are not required to return or re-label existing product that was released prior to September 22.
Quick
Shots
•New pricing to apply from September
22, 2025.
•Decision taken at the 56th GST
Council meeting.
•Manufacturers & marketers must
update MRPs to reflect new GST rates.
•No direct penalties announced yet,
but non-compliance may invite action under Essential Commodities Act
(fines/jail).
This article has been contributed by Devashish Singh, Co-Founder, MrMed.
The largest pharmaceutical companies are engaged in researching and developing therapies for super speciality diseases such as cancer, Alzheimer’s, osteoarthritis and other chronic conditions that are relatively rare and extremely complex. Cancer, for example, has various stages and medications change based on tumor proliferation. However, the genes of patients also play an important part in determining suitable medication, especially with the advent of promising therapies such immunotherapy and targeted therapy. As you can imagine, developing such targeted therapies by studying gene mutations associated with certain cancers is a long process with billions of dollars spent on research and development. Only a small percentage of promising lab work ends up getting approved for end patient use. An even smaller percentage ends up becoming a “blockbuster” drug, generating revenue and profits for pharmaceutical companies and everyone in the value chain. These R&D based drugs are patented and have just 10-20 years (depending on when and where the patent was filed) before generics are introduced in the market.
However, the balance between profitability and affordability is a complex equation. Pharmaceutical companies need to generate profits from their “blockbuster” drugs to ensure continued infusion of capital to research and development while also keeping shareholder interests in mind. In fact, there have been occasions when large pharmaceutical companies take a merger & acquisition route when a “blockbuster” drug is expiring and the pipeline of drugs in various clinical stages or under R&D is not as strong. Therefore, free cash for such acquisitions are also part of contingency plans for pharmaceutical companies.
There is absolutely no doubt that large multinational pharmaceutical companies focus on the North America, Western Europe, Australia and Japan markets, where the healthcare ecosystem is insurance driven and the overall cost of healthcare is 20X-100X that in India.
However, pharmaceutical companies along with the government of India are slowly starting to introduce some of the patented therapies in India and adopt the below strategic approaches in reducing therapy cost:
There have been a few pilots on value-based pricing strategies, which involves setting the cost of medications in alignment with the benefits they deliver. This approach goes beyond basic economics of supply and demand and considers the tangible impacts on patient health, potential savings for healthcare systems, and broader societal benefits. Therefore, successful impact on the overall system generates higher profitability, which is a win-win. However, it is often difficult to agree upon the metric for “successful impact” and this involves building high trust.
Patient Assistance Programs
Patient assistance programs (PAPs), which are usually sponsored by pharmaceutical manufacturers are a vital step in saving overall therapy cost for patients. This is applicable in developing countries like India and is an initiative of pharma companies on request of various government and non-government organizations. The goal of these programs is to reduce the cost of therapy by providing free medication based on certain paid purchases. For example, through PAP, the cost involved in treating lung cancer through targeted therapy is reduced by 66%. My company, MrMed.in has helped thousands of patients enroll in patient assistance programs, which has truly changed lives.
Implementing Tiered Pricing Structures
Pharmaceutical companies employ tiered pricing strategies that reflect the economic conditions of different markets. Various factors such as GDP per capita, healthcare infrastructure and insurance coverage are considered when adjusting prices on a global level, making therapy more equitable. Either directly or through Patient Assistance Programs, the cost of therapy in India or China is very different from that in the USA or Japan.
Pharmaceutical Companies in India
Preventive Care & Early Detection
As the adage goes, “prevention is better than cure”. I would like to also add that early detection is still not a bad place to be at. The success rates are much higher and the cost of therapy is exponentially lower in earlier stages of disease, whether it be cancer, arthritis or chronic kidney disease. Therefore, annual screenings for breast cancer for women over the age of 40, and biennial screenings for those under 40. Similarly, genomic testing in consultation with a doctor experienced in genomics is also recommended. The government along with private organizations like MrMed have been conducted vaccination camps for cervical cancer wherein the HPV vaccine is administered to young girls and women, which will result in long term reductions in cervical cancer statistics. Regular health check-ups and a healthy lifestyle will not only reduce the prevalence of chronic diseases and the need for expensive treatment, but will also promote a healthier and more productive country.
Transparency in the Supply Chain
The most important aspect of improving affordability of super speciality medicines is to have a clean value-based supply chain. Neighborhood chemists and pharmacies do not hold these medicines in inventory due to lack of awareness, high inventory cost, special storage requirements and relatively lower demand in their particular catchment area. Therefore, the standard margins that generally dictate pharmaceuticals in India, do not apply for super speciality medicines. Often times, “special rates” are given to various distributors or other wholesalers based on volumes and ability to move inventory. This can often lead to differential pricing in the supply chain, with patients seldom benefiting. Through data analysis and inventory forecasting, supply side aggregation of “special rate distributors” and efficient marketing to generate demand, MrMed is able to reduce the cost of super speciality medicines by up to 85%.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. Abbott India Ltd has approved the content in this post.
The character of the pharma industry is such that many people tend to think of it as a very different industry from the rest. It is perhaps one of the most developed sectors in recent times.
Talking about the pharmaceutical industry,Abbott Laboratories is one such company that has made a substantial global impact with its innovative pharma and medical products. Its global headquarters are present in Abbott Park, Illinois, United States. The company is spread across countries in Asia Pacific, Europe, the Middle East, South Africa, and the Americas. Founded in 1888 by Chicago medic Wallace Calvin Abbott, Abbott Laboratories has made a gigantic name for itself in India as well, with its subsidiary Abbott India Limited, which has its headquarters in Mumbai.
Dive into this article for further information on Abbott India Ltd. Read about its mission and vision, key products of Abbott India, business and revenue model, CSR activities, and more.
Abbott India Limited is a subsidiary of Abbott’s international pharmaceutical business in India. It is one of the country’s fastest-growing pharmaceutical firms today. Boots Pure Drug Company (India) Ltd was the initial name under which Abbott India Ltd was founded in 1944. It runs a production plant in Goa as well as a number of independent contractors and third-party producers located throughout the nation.
Abbott India Limited, an Abbott Laboratories subsidiary with its headquarters in Mumbai, offers reliable, high-quality medications in a variety of therapeutic areas, including women’s health, gastroenterology, cardiology, metabolic disorders, and primary care.
Abbott India Ltd is devoted to giving Indians access to high-quality healthcare through a combination of international and domestic goods. The company has its development and medical team that generates products and clinical trials that are specifically suited to the demands of the Indian market. Its staff members try to create high-quality, high-volume formulations utilizing methods that are economical. Additionally, Abbott’s skilled staff members are committed to guaranteeing adherence to global quality standards.
Some of Abbott’s well-known products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip in the medical equipment, diagnostics, and nutrition product businesses.
Abbott India’s CSR Activities
Abbott India is also involved in many corporate social responsibility activities that focus the society in general.
Its therapy-shaping efforts are intended to enlighten and assist individuals in making educated decisions, dispel common misconceptions about illnesses, and increase accessibility and effectiveness. It has set up health clinics like Fibroscan and Liver clinics to help provide a quick, reliable, and timely diagnosis to people. Vaccination outreach programs to create awareness of flu. Abbott India has reached out to parents across more than 50 schools to create awareness and stress the importance of flu vaccines. More than 500 Menopause clinics were established pan India by Abbott India. The company has also executed around 100+ Pausetive Talks (awareness on menopause symptoms) for women across India in 12 regional languages, both digitally and physically.
Abbott India Ltd. – Industry details
India’s pharmaceutical sector is predicted to be worth $65 billion by 2024 and $130 billion by 2030. India’s pharmaceutical sector is currently worth $50 billion.
Patient expenditure on healthcare and medications is anticipated to increase for non-COVID-19 therapy as India’s economic growth is anticipated to continue.
Dr. Wallace Calvin Abbott was born in 1857. He is a graduate of the University of Michigan. When he founded the Abbott Alkaloidal Company, Dr. Abbott was a practicing physician. He was one of the first American doctors to use a novel method to distill alkaloids, the components of medicinal plants that have a therapeutic effect into a solid form like morphine, quinine, strychnine, and codeine. This strategy was helpful because it gave patients more dependable and efficient dosing. The business relocated from Ravenswood to North Chicago, Illinois, in 1922.
Abbott Laboratories was one of the forerunners of the scientific practice of pharmacy under the visionary direction of Dr. Abbott, and it expanded to address increasing global health demands by supporting new fields of medical research.
Vivek V Kamath
Vivek V Kamath – Managing Director, Abbott India Limited
Vivek V Kamath is the Managing Director of Abbott India Ltd. He has a degree in science with a focus on microbiology and a Master’s in Management with a focus on marketing. Mr. Vivek has more than 30 years of extensive and varied expertise in the healthcare industry, including the pharmaceutical, over-the-counter, and diagnostic industries. He has held many top leadership roles in reputable pharmaceutical firms, both Indian and MNCs, in a variety of geographical locations. Mr. Vivek also possesses significant functional knowledge in the fields of strategy, marketing, sales, and general management. He worked with MSD Pharmaceuticals, Roche Diagnostics in India, Novartis in Singapore, Ranbaxy, Pfizer in India, Fulford in India, Wockhardt, and Johnson & Johnson before joining Abbott.
Rajiv Sonalker
Rajiv Sonalker – CFO and Whole-Time Director, Abbott India Limited
Rajiv Sonalker is the whole-time Director and CFO of Abbott India Ltd. He is a fellow member of the Institute of Chartered Accountants of India and holds a Bachelor’s Degree in Science from the University of Bombay. Rajiv Sonalker served as Director of Finance at Bristol-Myers Squibb before joining Abbott India. In Germany and India, Rajiv has also worked with Voltas Ltd., Johnson & Johnson, and Sanofi-Aventis.
Abbott India Ltd. – Startup Story | How It Began?
The story of Abbott India began in the 1940s. The origin of the company is when Dr. Wallace Calvin Abbott founded its parent organization Abbott Alkaloidal Company in 1888. It was during this time when the production of “alkaloidal” medicine granules was introduced, which made it a big hit in the market. After making sufficient sales in the USA, Abbott established its first overseas affiliate in London in 1907; the company then acquired a Montreal, Canada, affiliate. Boots Pure Drug Company (India) Ltd. was the initial name under which Abbott India Ltd. was formed on August 22, 1944. On November 1st, 1971, the business was renamed The Boots Company (India) Ltd; on January 1st, 1991, it became Boots Pharmaceuticals Ltd. The name was changed to Knoll Pharmaceuticals Ltd on October 31, 1995, and then to Abbott India Ltd on July 1, 2002.
17 new products were introduced by Abbott India during the fiscal year that concluded on March 31, 2016, and they collectively generated 1.9% of the company’s net sales. The firm and Bharat Biotech India Limited entered into a license agreement during the reviewed year to commercialize vaccines in the immunology category.
The mission statement of Abbott India is, “to build life-changing technologies that keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines, and breakthroughs to manage your health.”
Abbott India Ltd. – Name, Tagline, Logo
Abbott India Limited Logo
Before Abbott India, the company’s name was Knoll Pharmaceuticals Ltd. The name was changed in 2002.
The tagline of Abbott Laboratories is, “Live Your Best Life, Now And In The Future”
Abbott India Ltd. – Business Model
Diagnostics, medical equipment, branded generic drugs, and nutritional goods make up the core businesses of Abbott, which have been expanded via acquisitions. The company through its subsidiary, Abbott India creates and sells more than 600 goods for medical professionals that support Indians’ overall health and well-being.
The extensive pharmaceutical portfolio of Abbott in India covers the complete spectrum of healthcare requirements for all phases of life, from illness prevention to treatment and cure. Abbott Healthcare Solutions represents one of the largest pharmaceutical portfolios in India, including some of the market’s most dependable goods. In the fields of dermatology, diabetes, cardiology, gastrointestinal, central nervous system, pain management, and orthopedics, it is widely regarded as a market leader.
In India, the top of their respective categories is occupied by trademarks like Stemetil, Haemaccel, Kenacort, Paraxin, and Neomercazole. Abbott India’s business also includes providing high-quality healthcare to those living in ultra-urban areas where access to these quality healthcare solutions is a challenge. With a high-quality, reasonably priced portfolio of products in the therapy areas of pain management, gastroenterology, and anti-invectives for diseases like typhoid, malaria, and respiratory infections, Abbott True Care is assisting in improving the health and well-being of the people in extra-urban towns.
Abbott India’s main business operations are divided into the following categories:
Nutrition – This is further divided into categories like Adult Nutrition (Ensure and ZonePerfect), Child Nutrition (Isomil, and Gain) Infant Nutrition, and other medicinal nutrition
Diagnostics – with focus areas like Core labs, Molecular, and Point of Care
Established Pharmaceuticals – branded generic drugs
Medical devices – offering high-end medical devices for diabetic care, vascular care (coronary and endovascular), rhythm management, and electrophysiology.
The superior financial success has constantly been a result of the robustness of its business model.
Abbott India Ltd. – Revenue Model
Abbott India Ltd. made 11.4% of its Revenue from Operations. For FY 2021-2022, the company has delivered impressive results with 14.1% growth in revenue and 15.6% in net profits over the previous year. The company mostly generates its revenue from its diversified pharmaceutical portfolio.
Abbott India Ltd. – Growth
With a 14.1% growth in revenue (from ₹4,310 crores in FY21 to ₹4,919 crores in FY22), Abbott India has added 10 new items to its major portfolios in the therapeutic areas of women’s health, gastroenterology, central nervous system, multi-specialty, and vaccines. It conducts business in Nepal, Sri Lanka, Maldives, and Bhutan. Abbott India’s emphasis on expanding its business in these nearby nations and helping people through its high-quality products is also growing. It has a robust distribution network of more than 8,600 stockists and 60 lacs, retailers.
Abbott India Ltd. – Advertisements and Social Media Campaigns
In 2020, Abbott India launched the ‘Don’t Wait for Life’ campaign to highlight the importance of health challenges through technologies and solutions. The advertising campaign emphasizes the value of pursuing one’s dreams without sacrificing the life one is already living. The ad talks about Abbott’s groundbreaking cardiac pumps enabling people to continue living normally even when they have heart failure.
The campaign was launched by a series of four videos that depict the stability of people with heart problems and diabetes, which are considered highly prevalent non-communicable health conditions in India.
Abbott India Ltd. – Awards and Achievements
The list of awards and achievements won by Abbott India are:
Abbott India Ltd won the ‘GOLDEN PEACOCK HR EXCELLENCE AWARD’ For the second consecutive year from the Institute of Directors
Abbott India Ltd was recognized by Avatar and Working Mothers as the “Best Companies in India”
Abbott India Ltd won the “Best Places to Work” For 8 consecutive years by Business Today
Abbott India’s Goa plant received the prestigious Abbott Global EHS Excellence award for upgrading the fire-fighting facility without business interruption. The plant also received the Best Plant award from Abbott Global.
Abbott India Ltd. – Competitors
Abbott India competes with the following top competitors:
Abbott India wants to keep placing a priority on developing novel medicines. The company further plans to introduce cutting-edge goods and services to the market. It believes this introduction is essential if it wants to revolutionize Indian healthcare.
FAQs
Who is the Managing Director of Abbott India Ltd.?
Mr. Vivek V Kamath is the Managing Director of Abbott India Ltd.
Investing in pharmaceutical stocks has become increasingly popular in recent years. The pharma sector continues to grow at a rapid pace. With the UK boasting a number of strong pharmaceutical companies, there are plenty of options for investors looking to make a long-term commitment. Here are 3 UK Pharma stocks I’d buy to get rich in 10 years:
1. AbbVie (NYSE: ABBV)
AbbVie is a leading global biopharmaceutical company that specialises in a range of therapeutic areas including oncology, immunology, neuroscience, and virology. AbbVie’s blockbuster drug Humira is a top-seller, and the company expects to profit significantly from its anti-inflammatory drugs Rinvoq and Skyrizi. AbbVie’s pipeline includes 20 different programs in phase 3 testing, making it a great long-term investment.
2. Bristol Myers Squibb (NYSE: BMY)
Bristol Myers Squibb is a leading global biopharmaceutical company that specialises in a range of therapeutic areas including oncology, immunology, and cardiovascular disease. BMS is conducting more than 50 clinical testing programs and recently won approval in the US for two cell therapies. It also manufactures Reblozyl, which treats anaemia in patients with blood disorders and myelodysplastic syndromes.
3. Celadon Pharmaceuticals Plc (AIM: CEL)
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company with a primary focus on growing indoor hydroponic high-quality cannabis for use in approved medicines. The company is committed to improving quality of life by researching and manufacturing cannabinoids for use in approved medicines with an initial focus on chronic pain. The company also has a majority stake in LVL Health, a chronic pain clinic, alongside a minority stake in cannabinoid-based biopharmaceutical company Kingdom Therapeutics. This provides Celadon with a direct inroad into its target chronic pain market, making it a great long-term investment.
Investing in pharmaceutical stocks can be a lucrative and rewarding long-term commitment. I would be particular keen on investing in Celadon Pharmaceuticals PLC due to the company’s involvement in the legalisation of cannabis. CBD is a huge market as it is, and with the new data being provided to the regulating bodies, the stigma surrounding cannabis will soon be cleared for a lot of people.
Why pharmaceutical stocks?
Pharmaceutical stocks are attractive to investors for a few reasons.
1. Demand
The demand for pharmaceuticals is relatively constant and has been for the past decades. People will always need medication to treat illnesses and diseases, and as the population continues to grow and age, the demand for pharmaceuticals is likely to increase. Additionally, the pharmaceutical industry is highly research-driven, and companies are constantly working to develop new drugs to treat illnesses and diseases. This means that pharmaceutical companies are able to charge premium prices for their products and generate high profit margins.
2. Regulation
Furthermore, the pharmaceutical industry is also highly regulated – and for good reason.
This provides a great level of stability for investors, as companies must go through a rigorous approval process (FDA) before they can bring a new drug to market. This helps to ensure that only safe and effective drugs are available to patients while providing investors with a prospective reflection on the companies potential ROI on a new drug.
3. The Pipeline
In addition, one of the key factors to consider when investing in pharmaceutical stocks is the strength of the company’s pipeline. What does that mean?
Well, a strong pipeline of new drugs in development increases the chances of potential growth, as the company will be able to generate revenue from new drugs and medications they bring to the market. Additionally, companies with a diversified pipeline are less likely to experience significant drops in revenue if one drug in their portfolio loses patent protection or is not as successful as expected.
What about risk factors?
As with any investment, there is a certain risk involved.
Aside from traditional risks that come with an investment into stocks, here are a few more risk factors that apply to pharma companies specifically.
1. Regulatory Issues
One of the key factors in the success of a drug is whether it will be approved by regulatory bodies, such as the FDA or EMA. There’s always the possibility that a new drug in development may not be approved, which can cause significant delays or even the failure of the product.
2. Patent Issues
When a drug’s patent expires, other companies can begin manufacturing and selling generic versions of the drug, which can significantly reduce the original company’s revenue as many tend to outsource this to the middle east or India. This can in turn have a major impact on a company’s profits and overall financial stability.
3. Adverse Events
Certain drugs can have unexpected side effects, and when it’s the case, the drug may be withdrawn from the market, leading to significant financial losses for the company, and reputational damage or even law suits.
4. Competitions and Innovation
New competitors and advances in technology can make a company’s products obsolete and lead to a decline in revenue and profits. Especially the biotechnology sectors has seen rapid growth in the past years. Biotechnology and genetic engineering have allowed for the production of highly targeted and personalized therapies, such as monoclonal antibodies and gene therapies, which have the potential to further revolutionize the treatment of various diseases.
Consider these risk factors before you ultimately decide whether to invest into a stock or not.
Conclusion
Overall, investing in a few promising pharmaceutical stocks can be a great long-term commitment, as the demand for pharmaceuticals is relatively constant and the companies are constantly researching and developing new drugs.
The above-mentioned companies, namely AbbVie, Bristol Myers Squibb and Celadon Pharmaceuticals Plc are great options for explore if you’re looking to make a long-term commitment by investing into the the pharmaceutical industry.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Alembic Pharmaceuticals.
Pharmaceutical manufacturing goes through many stages before producing a single medicine. This industry is by far one of the most successful industries of today. The success rate of these pharmaceutical manufacturing has resulted in outstanding progress in the medical world.
With its headquarters in Vadodara, Alembic Pharmaceuticals Ltd. is a global pharmaceutical firm based in India. Founded in 1907, Alembic Pharmaceutical produces pharmaceutical goods, pharmaceutical ingredients, and pharmaceutical intermediates. It is also referred to as the market leader in India’s macrolides anti-infective medication category. Alembic Pharmaceuticals belongs to the Alembic Group, which was founded by Prof. T.K. Gajjar, Prof. Kotibhaskar, and B. D. Amin.
Learn all about Alembic Pharmaceuticals’ success story, its startup story, mission, and vision, and its business and revenue model.
Alembic Pharmaceuticals Ltd. works on the production and marketing of Indian formulations, active pharmaceutical ingredients, international generics, and pharmaceutical intermediates. The company’s corporate office and headquarters are located in Vadodara, Gujarat, India, while its production facilities are spread out between Sikkim and Panelav, both in Gujarat. Active pharmaceutical ingredients (APIs) and formulation production are handled by its Panelav factory, while formulation production for India and unregulated export markets are handled by its Sikkim plant. Recently, the company’s production capacity was increased by the addition of three new plants for oral solids and injectables for cancer, general injectables, ophthalmology, and oral solids, bringing the total to six state-of-the-art facilities that epitomize manufacturing excellence.
Alembic Pharmaceuticals is among the most reputable suppliers of specialty medications in India for a range of acute and chronic treatments. In the domestic market, it provides a range of high-quality items that address ten therapeutic categories. Alembic Pharmaceuticals is renowned for providing its customers with deliveries on time.
Alembic Pharmaceuticals’ CSR initiatives
The Alembic CSR Foundation was founded in 2015 to uplift and strengthen communities across various areas of Education, Health, and Overall Community Development.
The company’s plantation initiatives have resulted in 1,300 saplings being planted over the past 5 years in 4 panchayats of the Panchmahals district, including 100 saplings planted in Gopipura village during 2020-2021. Alembic’s CSR foundation has built 242 domestic toilets in the Karkhadi and Pindapa panchayats in the Vadodara district as part of its sanitation activities. In the Vaseti Panchayat villages of Tajpura, Dadiyapura, and Shivjipura, it has also constructed 346 domestic toilets.
Alembic Pharmaceuticals – Industry details
Over the past two decades, India’s pharmaceutical business has expanded at a compounded growth rate of 16% for exports and 11% for the domestic market.
Through 2025, the worldwide pharmaceutical industry is anticipated to expand at a 3-6% CAGR, with a projected market value of $1.6 trillion. This does not include COVID-19 vaccine investment, which is expected to total $157 billion overall through 2025.
Alembic Pharmaceuticals – Founder and Team
Alembic Pharmaceuticals is managed by Chirayu Amin, the Chairman & CEO of the company.
Chirayu Amin- Chairman & CEO
Chirayu Amin
Chirayu Amin is a multimillionaire businessman from India who also oversees cricket. Amin has guided the organization through the shifting demands of modern business while maintaining its legacy.
He got his MBA degree from Seton Hall University. Furthermore, Chirayu Amin served as the Federation of Indian Chambers of Commerce’s chairman. Malika Chirayu Amin, his wife, has been listed by Kotak Wealth Hurun as one of India’s wealthiest women in 2020.
Chirayu was also the Baroda Cricket Association’s president. He has received the Federation of Gujarat Industries (FGI) Lifetime Achievement Award in January 2021. According to Forbes, Chirayu Amin’s net worth as of May 2021 was US$1.8 billion.
Pranav Amin
Alembic Pharmaceuticals Ltd’s Managing Director, Pranav Amin, is in charge of the division’s global business operations. He is a graduate of Thunderbird University in the United States with an MBA in International Management and a degree in Economics/Industrial Management from Carnegie Mellon University in Pittsburgh, USA. Pranav Amin is considered a fantastic people leader who directs the company via participation, empowerment, and autonomy.
Alembic Pharmaceuticals – Startup Story
In 1907, Alembic Chemical Works, which is now Alembic Pharmaceuticals Ltd., began producing tinctures and alcohol at its Vadodara facility. The business subsequently started producing sulfur medications, vitamins, tonics, and cough syrups around the 1940s.
Additionally, Alembic started producing penicillin in the 1960s. Lal Bahadur Shastri, the Indian Prime Minister at the time, dedicated this Alembic factory to the production of penicillin in 1961.
The pharma company immediately started producing vitamin B12 in large quantities in 1967.
In the field of antibiotics, Alembic started producing erythromycin in India for the first time in 1971, not long after the manufacturing of penicillin was started. Alembic also created and introduced the erythromycin brand “Althrocin.” Althrocin surpassed all other erythromycin brands in sales in India in 1997.
After a few years, Alembic got ISO 14000 accreditation in 2000 for its Vadodara plant. Following the distribution of 133,515,914 equity shares worth $2 each to the shareholders of Alembic Ltd. in 2010, Alembic Pharmaceutical Ltd. separated from Alembic Ltd. As a result, Alembic Ltd.’s ownership of Alembic Pharmaceutical decreased from 100% to 29.18%.
Alembic Pharmaceuticals Ltd.’s equity shares were placed on the Bombay Stock Exchange and the National Stock Exchange of India in 2011.
Around 2012, the company revealed the dermatology department in Indian markets with eight new products. In 2017, Alembic Pharmaceuticals based the manufacturing facility for Oncology medicines in presence of the then Hon’ble Chief Minister of Gujarat, Shri. Vijay Rupani.
Alembic gained a $250 million sales milestone in the USA front end.
Alembic Pharmaceuticals – Mission and Vision
Alembic Pharmaceuticals’ mission is, “To improve healthcare with innovation, commitment, and trust.”
The company believes that the four pillars of quality, capability, customer centricity, and diversity are the key enablers for its future growth.
Alembic Pharmaceuticals – Name, Tagline, Logo
Alembic Pharmaceuticals Logo
Alembic Pharmaceuticals – Business & Revenue Model
Alembic Pharmaceuticals Ltd. runs its business as a vertically integrated pharmaceutical company. Each of the company’s business areas may benefit from the premium items in its varied range, which command greater margins.
Alembic deeply invests in developing a portfolio of specialized, specialist medications that offer chances for long-term revenue development. It takes advantage of its manufacturing and intellectual edge, through strategic acquisitions that offer prospects for internal product development and value enhancement.
Domestic Business:
Alembic offers products in 10 therapeutic areas including Cardiology, Orthopaedic, Ophthalmology, Nephro/Uro, Anti-Diabetic, Gynaecology, Gastrology, Dermatological, Anti-Infective, Cold, and cough with 185 brands in the market.
Most of its caters to several chronic and acute therapies and around 1,75,000 doctors in India.
It has two R&D centers situated in Vadodara (Gujarat), and Hyderabad (Telangana)
Alembic’s formulation facility is located in Sikkim, Panelav, Karkhadi
Alembic’s two brands are in the top 300
1.4% market share in the Indian pharma space
Alembic APIs are supplied to formulators in over 60 countries across the globe
Alembic has generated Rs 1,497 crores (2020-2021) in domestic business
International Business
Alembic is present in the US, Europe, Canada, Australia, Brazil, South Africa, and other markets
Offers diversified products in various therapeutic areas
The company has launched more than 90 products in the USA till now
It has one R&D facility in New Jersey, USA
Alembic generated around Rs 2,942 crores (2020-2021)
The company’s international business grew by 62% in Quarter 1 FY21 on a Y-o-Y basis, this excludes the USA.
As per reports, Alembic spent around 12.4% of its revenue on R&D activities during 2020-2021 to upscale its generic business to the international markets.
Alembic Pharmaceuticals – Growth
Alembic Pharmaceuticals claims that it had enormous growth and a huge increase in market share for Azithral OSD. The company also established itself as a serious player on a worldwide scale since azithromycin was a crucial drug in the management of COVID-19. With a 30% market share of the domestic formulation market in India, it is one of the biggest makers of azithromycin.
The implementation of the Laboratory Information Management System (LIMS) in its plants to ensure smooth workflow and data tracking, as well as the Quality by Design (QbD) initiative to improve the safety and efficacy of its products, are just a few of the significant initiatives carried out by the company in the recent years.
Alembic Pharmaceuticals – Mergers and Acquisitions
During its 115 years of legacy, Alembic has acquired some renowned business operations. The year 2012 saw the announcement of Paragraph IV ANDA litigation between Alembic Pharmaceuticals and Breckenridge Pharmaceutical, Inc., and Pfizer about desvenlafaxine (Pristiq). Additionally, Alembic and AccuBreak Pharmaceuticals Inc. engaged in product development and license arrangement.
Alembic Pharmaceuticals and Ranbaxy Pharmaceuticals Inc. engaged in an out-licensing arrangement in 2013 to allow Alembic Pharmaceuticals to commercialize its medications in the USA. Later after one year, Alembic Pharmaceuticals entered into joint ventures with Adwiya Mami SARL Algeria through its wholly-owned subsidiary Alembic Global Holdings, expanding its business in Algeria. Besides this, Alembic also signed an exclusive contract with Novartis around 2015, expanding its business in Switzerland.
Here’s the list of acquisitions made by Alembic Pharmaceuticals Ltd.:
Date/Year
Acquiree Name
Amount
March 29, 2022
Aleor Dermaceuticals
–
November 1, 2017
Orit Laboratories
–
2007
Dabur’s non-oncology formulation business
Rs 150 crores
Alembic Pharmaceuticals – Funding and Investors
In a qualified institutional placement (QIP) on Thursday, Alembic Pharma collected Rs 750 crore from investors including Tata Mutual Fund, HDFC Life, Sundaram, Bajaj Life, and Nippon India Mutual Fund.
Alembic Pharmaceuticals – Awards and Achievements
Alembic Pharmaceuticals has won many awards and achievements, those are:
Excellent Efforts in Risk Management Award
Alembic Pharmaceuticals was listed in Forbes’ 2016 list of “India’s Super 50 Companies.”
Job Safety Analysis (JSA) Finished as the first runner-up in Job Safety Analysis (JSA) at CII Industrial Safety Summit 2016
Gujarat Best Employer Brand Award -Recognised for the ‘HR Event of the Year’ and ‘Outstanding Contribution to the cause of Education at the Gujarat Best Employer Brand Awards 2017
Alembic Pharmaceuticals received the Thomson Reuters Top 50 Indian Innovators Award in 2015
Alembic Pharmaceuticals – Competitors
Below is the list of competitors of Alembic Pharmaceuticals:
Presently, Alembic Pharmaceuticals is establishing new capacities and funding R&D initiatives with more favorable risk-return profiles. In addition, its consumer interaction skills are driven by its US marketing team, who also assists them in adding more value. It further plans to take advantage of scale economies and guarantee an adequate supply for its clients by gradually investing in boosting capacity.
FAQs
Who is the CEO of Alembic Pharmaceuticals?
Chirayu Amin is the CEO of Alembic Pharma.
Is Alembic Pharma an MNC?
Yes, Alembic Pharma is an Indian Multinational Company based in Vadodara, Gujrat.
What is the rank of Alembic Pharmaceuticals?
Alembic Pharma ranks 18 in India in terms of market cap.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Innovexia Life Sciences Pvt. Ltd.
From the 19th century onwards, the world saw how pharmaceutical science improved remarkably. It was during that period when the pharmaceutical industry witnessed some major developments in new classes of pharmaceuticals. Scientists and biologists worked hard to make prominent progress with their in-depth research to create some of the vital drugs that many of us are familiar with today.
Innovexia Life Sciences Pvt. Ltd. was established in 2011, that produces, trades distributes, and supplies a large variety of pharmaceutical medicines and injections. It is also regarded as one of the leading pharmaceutical franchise companies in Chandigarh.
Let us find out more about Life Sciences Innovexia Pvt. Ltd’s success story, its founder, the type of business model they have, how it generates its revenue, and so on.
Innovexia Life Sciences Pvt. Ltd. – Company Highlights
The Innovexia Life Sciences Pvt. Ltd is a pharma company that is engaged in offering a wide variety of products ranging from advanced antibiotics, high-quality vitamins, minerals, protein, chemicals, and other materials. The company is also engaged in the services of marketing a wide range of medicines under the business segment – the PCD Pharma franchise. Innovexia also offers contract manufacturing services to various clients to help them in the smooth functioning of the business. It deals in manufacturing products like tablets, capsules, derma range, ayurvedic products, herbal products, and many more at its technologically advanced manufacturing unit, which is GMP and WHO-approved. The company deals in brands like Duotime-S, Innoscab, Rightpro Plus, Innodent, and many more.
Innovexia Life Sciences is considered to be one of the emerging pharma companies in India.
Innovexia Life Sciences Pvt. Ltd. – Industry Details
In terms of quality manufacturing and value, the Indian Pharmaceutical industry comes at the 14th position. As per a survey, the domestic pharma market is anticipated to grow at least 3 times more in the coming years and is likely to reach $50-60 billion by 2025.
Innovexia Life Sciences Pvt. Ltd. – Founder
Innovexia Life Sciences is founded by Sandeep Khajuria.
Sandeep Khajuria Founder-Innovexia
Sandeep Khajuria
Sandeep Khajuria is presently the Chairman and Managing Director at Innovexia Life Sciences. He is a well-known and respected figure in the pharmaceutical sector. Mr. Sandeep Khajuria has more than 25 years of expertise in this field. He has worked in various sectors like Human Resources, Sales & Marketing, and Production & Distribution, at different levels in popular companies like Dr. Reddy’s Laboratories & Cipla Limited.
Innovexia Life Sciences Pvt. Ltd. – Mission and Vision
Innovexia Life Sciences’ mission statement is, “To become a leading Pharmaceutical Company in India in the sphere of excellence manufacturing, innovation, formulation, marketing and to escalate the business from the threshold of country and to become a forerunner in overseas.”
The company aims to improve the health of every person by offering its customers a wide range of pharmaceuticals.
Innovexia Life Sciences Pvt. Ltd. – Name, Tagline, Logo
The tagline of Innovexia Life Sciences is, “Life through Innovation”
Innovexia Life Sciences Pvt. Ltd. – Business & Revenue Model
Innovexia Life Sciences business involves offering three types of services – High-quality Pharma products, PCD Pharma Franchise, and Contract Manufacturing.
High-quality Pharma products
Innovexia manufactures some first-rate pharmaceutical products at affordable prices. All of its products have been certified by ISO, WHO, and GMP. It creates medicines and drugs for Dental, Gastro, Injections, Herbal, Nasal Spray, Pediatrics, Syrups, Lotions, Urology, Tablets, and Capsules.
PCD Pharma Franchise Business
Innovexia is also engaged in offering marketing solutions for pharma startups from across the country. The company seeks Pharmacy dealers, manufacturers, and distributors to become a part of the Pharma Franchise in Chandigarh. With this initiative, the company aims to open doors for other pharma startups to help them achieve substantial growth with a remarkable profit margin. Its key focus area is Allopathic PCD Pharma Franchise across India. The company also targets Baddi as its main location with the PCD Pharma Franchise in Baddi (Himachal Pradesh). Apart from these two locations, it is also looking for companies for District wise PCD Franchise in other states such as – Andhra Pradesh, Assam, Bihar, Bangalore, Chhattisgarh, Goa, Odisha, Gujarat, Rajasthan, Tamil Nadu, Kerela, Uttar Pradesh, Maharashtra, Madhya Pradesh, Tripura, Uttarakhand among many others.
Contract Manufacturing
Innovexia Life Sciences also takes up the manufacturing process of other companies. The company does its business with full transparency without any hidden costs. It also claims that its manufacturing units are well-equipped with the latest technology and machines to make sure that they deliver maximum output in a given time frame. Furthermore, the company also takes care of the packaging of its drugs. It uses quality packaging techniques so that the drugs are free from any damage. All in all, Innovexia Life Sciences focuses on every bit of the manufacturing process.
Innovexia generates its maximum revenue through the three services it offers. To be precise, the company gains through its contract manufacturing process as it is a market leader in the domestic contract manufacturing sector in the pharmaceutical industry.
Innovexia Life Sciences Pvt. Ltd. – Award & Achievement
Innovexia Life Sciences has won the following awards:
Innovexia Life Sciences has won the India 5000 Best MSME Award For Quality Excellence – 2020.
Innovexia Life Sciences received the IndiaMart TrustSeal certificate in 2013
Innovexia has been certified by ISO 9001: 2015 for Quality Management System
Innovexia Life Sciences was recognized by Indiamart for the ‘Leaders of Tomorrow Award.
Innovexia Life Sciences Pvt. Ltd. – Competitors
The list of top competitors of Innovexia Life Sciences are:
Innovexia Life Sciences is actively looking for pharma partners in other states besides Chandigarh and Baddi to expand its PCD Pharma Franchise Business. The company is always striving to improve the quality of its pharma products to enhance patient’s life with its innovative and effective products.
FAQs
Who is the CEO of Innovexia Life Sciences?
Sandeep Khajuria is the CEO of Innovexia Life Sciences.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Piramal Enterprises.
If you were to start a business, you would require considerable time and effort to maintain the legacy. For businesspeople to run a business is not an easy job. It needs dedication and strategic planning to be successfully managed.
There are some entrepreneurs who like to take up challenges and diversify their businesses into multiple markets or industries. To put it simply, this type of business is called a conglomerate. As a matter of fact, India is home to many such conglomerates and over the past few years, it has witnessed some major developments with many growth-oriented policies.
In this article, we are going to share some the story of the Piramal Group, which is India’s leading global business conglomerate company. Headquartered in Mumbai, Piramal Group was founded by Ajay Piramal in 1984 with varied expertise in sectors like Pharma, Financial Services, and Real Estate.
Find out more about Piramal Group’s startup story, its key people, what are its marketing strategies, its revenue model, challenges faced, funding and investors, and many more in the article further.
Piramal Group is a multinational company with holdings in pharmaceuticals, healthcare information management, life sciences, financial services, and real estate. Started by Ajay Piramal in 1984, Piramal Group now has offices in almost 30 countries and a team of over 10,000 people working from various cultures and regions.
The Piramal Group works by offering diversified commercial services under different categories such as Piramal Enterprises Ltd. (PEL), Piramal Pharma Ltd., Piramal Realty, and Piramal Foundation.
Pfizer’s UK manufacturing site in Morpeth was purchased by the company in 2006. Piramal Group signed an agreement with Merck Pharmaceuticals in 2007 to collaborate on medication research and discovery. It secured a second medication research agreement with Eli Lilly and Company in 2008.
Piramal Group – Founder and Team
Piramal Group was founded by Ajay Piramal in 1984.
Ajay Piramal
Ajay Piramal is the Chairman of the Piramal Group. He was born on August 3, 1955, in Rajasthan, India to Gopikisan Piramal and Lalita Piramal. Ajay Piramal earned a bachelor’s degree in science from Jai Hind College and the Basantsingh Institute of Science at the University of Mumbai, and a master’s degree in management studies from the Jamnalal Bajaj Institute of Management Studies at the University of Mumbai. He also did a six-week Advanced Management Programme at Harvard Business School in 1992. He has been awarded an honorary doctorate by Amity University in India, as well as an honorary doctor of science by IIT Indore.
Ajay Piramal has received many awards and honors. To name a few, he received the Honorary Commander of the Order of the British Empire (CBE) in 2022 for services to the UK-India trade relationship, Business Leader of the Year Award 2018, CNBC Asia’s India Business Leader of the Year Award 2018, Outstanding Philanthropist 2013 and 2014, Forbes Philanthropy Awards, Special Achievement Award, Asia Pacific Entrepreneurship Awards (APEA) 2018 and many more.
Ajay Piramal plays many roles. He is the Non-Executive Director of Tata Sons Ltd. In addition, he is on the Board of Advisors at India’s International Movement to Unite Nations. He has remained an invitee to the World Economic Forum for the last 20 years.
Ajay Piramal’s wife is Dr. Swati Shah Piramal, who is the Vice Chairperson of Piramal Group. They have two children. Nandini Piramal D’Young, their daughter is married to US citizen Peter D’Young. Anand Piramal, their son, is married to Isha Ambani Piramal, daughter of Mukesh Dhirubhai Ambani, and his wife Nita Dalal Ambani. Ajay Piramal’s net worth was projected to be $3.7 billion as of June 2022.
Dr. Swati Shah Piramal
Born on 28th March 1956, Swati Shah Piramal is an Indian Scientist and Industrialist, and the Vice Chairperson of the Piramal Group. In 2012, the President of India awarded her the Padma Shri, one of India’s highest civilian accolades, for her contributions to the scientific and technology industries.
Dr. Swati Piramal was the first woman to serve as President of India’s Apex Chamber of Commerce. Along with this, she is also a member of the Harvard Board of Overseers and the Dean’s Advisor to Harvard Business School and the Harvard School of Public Health.
She has founded Mumbai’s Gopikrishna Piramal Hospital and has led public health initiatives against chronic diseases such as osteoporosis, malaria, tuberculosis, epilepsy, and polio.
Dr. Swati Piramal has a medical degree from Mumbai University. She holds her master’s degree from the Harvard School of Public Health. For her various outstanding contributions to healthcare and philanthropic movements, Dr. Swati has been the recipient of many accolades. BMA Management Woman Achiever of the Year Award (2005), Nominated for the Forbes Philanthropy Awards 2013 in the Outstanding Philanthropist category, Listed in the 25 Most Powerful Women, and is now a part of the Hall of Fame of Most Powerful Women among many others.
Piramal Group – Mission and Vision
The mission statement of Piramal Group is, “We aim to serve our customers, community, employees, partners, and all other stakeholders by putting their needs and well-being first”
Piramal Group stays true to its following core values:
Knowledge
Action
Care
Impact
Piramal Group – Name, Tagline, and Logo
Piramal Group is named after the surname of the Piramal family.
The logo of Piramal Group was designed by taking inspiration from ancient times, which is the universal symbol of the Gyan Mudra. The symbol Gyan Mudra is often practiced in yoga, dance, and meditation. As seen, it displays a hand doing the mudra with each finger symbolizing one of the five elements – Air, Water, Earth, Fire, and Sky.
The tagline of Piramal Group is, “Doing Well and Doing Good”
Piramal Group – Business & Revenue Model
Piramal Group is a conglomerate industry whose business is divided into three major segments – Real Estate, Pharma, and Financial Services. It provides diversified commercial services. The firm operates its business in 30 nations, as well as has a worldwide brand presence in over 100 markets.
Piramal Group’s biggest business is its Piramal Enterprises Ltd. (PEL). PEL recognized an opportunity to develop its pharma business and invested in the local formulation sector while the Indian pharmaceutical industry was focused on overseas generics.
Piramal Enterprises Ltd, Piramal Realty, and Piramal Foundation are the three main components or part of the Piramal Group business.
Here’s taking a brief look into the business segments of Piramal Group:
Piramal Enterprises Limited –
Previously known as Piramal Healthcare Ltd., Piramal Enterprises Ltd. accounts for the largest company of the Piramal Group.
It is further divided into two categories –
Piramal Financial Services
It is active in business verticals by offering financial services such as
Piramal Capital & Housing Finance Limited (PCHFL) – It is a home financing corporation registered with the National Housing Bank (NHB) and involved in a variety of financial services companies. It offers wholesale and retail finance alternatives across industries. It also has customized financing solutions for the hospitality sector.
Piramal Alternatives (PA) –It offerscustomized finance options for high-quality corporations seeking to enhance their growth.
Piramal Credit Fund (PCF) – PCF is a sector-agnostic fund that has received a significant capital commitment from CDPQ (Caisse de dépôt et placement du Québec) to invest in mid to large-sized corporations across industries.
India Resurgence Fund (IndiaRF) –By taking a flexible strategy approach, IndiaRF is an equal joint venture between Piramal Enterprises Limited and Bain Capital Credit. It invests capital in the form of both loans and equity, in distressed to control circumstances in the Indian market. It has a dedicated website for IndiaRF – www.indiarf.com
Piramal Pharma Ltd. (PPL)
The Piramal Group’s Piramal Pharma provides a range of specific goods and services with the latest technological advanced manufacturing capabilities that are spread over 15 locations and a global distribution network in over 100 countries. It has services such as Pharma Solutions (the manufacturing unit),Critical Care (Complex Hospital Generics business), and Consumer Products Division (CPD) which sells over-the-counter medications. The company is also engaged in the ophthalmic category by teaming up with Allergan India. It is one of the leading specialty pharmaceutical companies in the ophthalmic category that offers high-quality medication and devices to treat diseases such as glaucoma, eye infections, and inflammations.
Piramal Realty
The Piramal Group ventured into the business of Real Estate in 2012 under the brand name Piramal Realty. It has architectural innovators KPF, HOK, Callison, Fosters, and Make among their collaborators, as well as worldwide structural consultants like BuroHappold, security and transportation specialists Max Security, and vertical transportation experts Lerch Bates.
Piramal Realty’s mission reads, “To build India’s most admired real estate company, admired not just for its scale & profitability, but also for its impact on the lives of its customers & the progress of our country.”
Piramal Realty’s top projects are – Piramal Mahalaxmi, Piramal Aranya, Piramal Agastya, Piramal Vaikunth, and Piramal Revanta.
Piramal Foundation
The company is vested in many philanthropic activities for which it established the Piramal Foundation in 2006. The foundation is actively engaged in the following projects:
Piramal Swasthya is a Karnataka-based health information helpline service named Arogya Vani.
Piramal Sarvajal, solar-powered water ATMs supply clean water in India.
Piramal School of Leadership provides education and women empowerment through the program – Piramal Fellowship and Principal Leadership Development Program (PLDP), Pratham delivers education to underprivileged children
Piramal Prize to recognize emerging organizations
Piramal Group – Revenue Growth
As of 2022, Piramal Group reported revenue of $1.8 billion (Rs 14,710 crores). The net income of the company stood at around $240 million (Rs 1,923.11 crores). The company generates about 40% of its revenue from outside the country.
Piramal Group – Funding and Investors
Piramal Enterprises has raised $737.1 million in three rounds of investment. Their most recent funding came from a Post-IPO Equity round on June 27, 2020. Their funding is supported by three investors. The most recent investors include The Carlyle Group and Standard Chartered Bank.
On December 18, 2019, Piramal Group raised $225 million in a single venture vehicle called India Resurgence Fund. The details are:
Date
Funding Round
Fund Amount
Investors
June 27, 2020
Post-IPO Equity
$490 million
The Carlyle Group
July 21, 2019
Post-IPO Debt
₹15 billion
Standard Chartered Bank
July 15, 2019
Post-IPO Debt
₹2 billion
Sachin Bansal
December 18, 2019
–
$225 million
Single Venture fund
Piramal Group – Mergers and Acquisitions
Piramal Enterprises has bought 5 businesses. On September 29, 2021, they acquired Dewan Housing Finance. They paid 3.8T for Dewan Housing Finance. Piramal acquired 11% of Vodafone Essar in 2011-12. The company sold its 11% stake in Vodafone India to Prime Metals, an indirect subsidiary of Vodafone Group, in 2014. The acquisition details are:
Date of Acquisition
Acquiree name
Amount
September 29, 2021
Dewan Housing Finance
₹3.8T
March 31, 2021
Hemmo Pharmaceuticals
₹7.8B
May 12, 2017
Walnut Medical
Undisclosed
January 31, 2017
Mallinckrodt – Specialty Products $170 million
August 16, 2016
Ash Stevens
$53 million
1999
Ceylon Company Limited
–
1984
Gujarat Glass Limited
Undisclosed
Piramal Group – Investments
On August 11, 2014, Piramal Enterprises invested in VGN Property Developers. This investment, Venture Round – VGN Property Developers, was worth $3 billion.
VGN Property Developers is a multibillion-dollar real estate firm based in Chennai.
Piramal Group – Advertisements and Social Media Campaigns
Piramal Capital and Housing Finance Ltd. (PCHF) launched a campaign in 2019 about their service called Bridge Loans. It is an ingenious tool that aids in the transition from selling an old house to purchasing a new one. Point of View Brandcom India is behind the concept of the advertisement. The ad shows how a person finds an apartment for his family but keeps the owner of the apartment waiting until he sells his old apartment.
Here’s what Mayank Jain, Head of Sales & Marketing at Piramal Capital & Housing Finance said about the campaign, “We at PCHF are focused on introducing products that seek to simplify the lives of our customers. A common problem that we encounter regularly is the wait to sell your old apartment to buy a new one. Our newly launched product – Bridge Loans is the answer to this problem. Through the film, we aimed to highlight this challenge and bring focus to our innovative product, specially designed to support our customers’ needs. We are pleased that Point of View Brandcom India has converted our brief into an effective product film by using humor to communicate our product offerings.”
Piramal Group – Awards and Achievements
Below is the list of the latest awards and achievements won by the Piramal Group:
Piramal Pharma recognized with the “2019 Global Customer Service Leadership Award” by Frost & Sullivan
Piramal Foundation recognized as ‘Socially Aware Corporate of the Year by Business Standard CSR Awards 2019
Piramal Capital & Housing Finance recognized as ‘Outstanding Company in Infra Finance’ at the 8th EPC World Awards
Piramal Realty was awarded the prestigious ‘Intelligent Enterprise Award 2018’ by Technology Senate in Pune on June 7, 2018
Piramal Housing Finance was recognized as the ‘Emerging Home Loans Provider of the Year at the MCHI CREDAI Golden Pillar Awards 2018 in Mumbai on May 5, 2018
Piramal Realty was conferred with the prestigious Mercer NDTV Employer Excellence Awards for ‘Excellence in Work-Life Balance’, in New Delhi on May 2, 2018
Piramal Glass USA was recognized as the ‘Suppliers of the Year 2018’ at TricorBraun’s 2019 Annual Sales Meeting & Supplier Showcase in St. Louis on January 23, 2019
Piramal Housing Finance was recognized as the ‘Emerging Home Loans Provider of the Year at the MCHI CREDAI Golden Pillar Awards 2018 in Mumbai on May 5, 2018
Piramal Pharma Solutions was recognized in all six categories including Capabilities, Compatibility, Expertise, Quality, Reliability, and Service at the recent CMO Leadership Awards, New York on March 21, 2018
The Piramal Group is targeting to expand its financial services by adding 100 branches in FY23. The firm is all set to launch different and high-yielding products and aims to strengthen its partnerships with fintech and consumer tech firms. With their recent acquisition of debt-ridden DHFL, the company is planning to go for low-cost acquisitions.
FAQs
Who is the CEO of Piramal Group?
Peter De Young is the CEO of Piramal Group.
How much is Ajay Piramal worth?
The net worth of Ajay Piramal is 940 Crores.
Where is the head office of Piramal Group?
The head office of Piramal Group is in Mumbai.
How many companies are there under the Piramal Group?
This article is contributed by multiple Startup founders from different fields.
Indian startup ecosystem proved to be massive in the year 2021. With a fine number of unicorns, startups from different industries, be it tech, healthcare, food, fintech or others are making everyone’s head turn. Every industry is paving its way and is turning into something unimaginable. The year 2022, seems to be getting even more interesting and jaw-dropping.
In this article, entrepreneurs from various fields shared their views about the industries that they feel are going to be the hot topics in the startup ecosystem, this year. So, let’s take a look.
Rohit Sahni | CEO & Founder, WK Life
Rohit Sahni | CEO & Founder, WK Life
Looking at the current scenario of a possible third wave of Covid-19, I think the hottest topic of 2022 would be how to survive another slowdown in the industry. It could also be the change in the consumer behavior due to lockdown, as we did see a change in the consumer behavior after the previous lockdown. Other than this digital prominence would also be one of the hot topics, owing to the Covid-19 scenario.
Abhinav Mital | Founder, The WorldGrad
Abhinav Mital | Founder, The WorldGrad
2022 is likely to see a continuation of the trends from last year and the massive adoption of technology in all aspects of our lives. Startups will continue to compete with each other to better service levels and go one up on each other whether it is grocery delivery or financial services. With plenty of capital flowing freely in the market, customers will continue to be spoilt for choices. It is expected to see startups in the hi-tech space emerge, leveraging the use of AR or VR to enhance quality provision and introduce a new dimension for customers. Some of the sectors to watch out for will be fintech, ed-tech, health tech, and cleantech in both the direct-to-customer and business-to-business formats.
Ankur Singh | CEO & Founder, Witzeal Technologies Pvt. Ltd
Ankur Singh | CEO & Founder, Witzeal Technologies Pvt. Ltd
India is becoming the world’s fastest-growing start-up ecosystem. As we move into the new year, technological innovations in any and every vertical will continue to drive the startup ecosystem. Partnerships between start-ups and large international entities are essential for the advancement of technological advancements, as well as the long-term growth of enterprises of all kinds.
I believe the future of online gaming in India lies in the innovations and creativity leading to providing a personalized experience to gamers. Moreover, we foresee the employment and hiring landscape witnessing a sharp rise along with the players choosing their profession as gaming.
Apu Pavithran | CEO & Founder, Mitsogo
Apu Pavithran | CEO & Founder, Mitsogo
At the forefront, most startups would look to increase viable partnership opportunities with other organizations. India is one of the fastest-growing hotspots for unicorn start-ups, so there will definitely be a stronger collective of unicorn start-ups with better investment opportunities. The post-pandemic world opened up a lot of opportunities for the start-up community. Most of them are looking at effective remote work/hybrid work opportunities to help improve employee well-being. Remote/hybrid work is beneficial to start-ups because it is cost-effective, and it largely helps employees in terms of commute, work-life balance, and improved productivity. Many start-ups will look into implementing cost-effective methods for workplace optimisation. Emerging technologies like 5G, AI, ML, edge computing, metaverse, will definitely create more opportunities.
Himanshu Arya | CEO & Founder, Grapes
Himanshu Arya | CEO & Founder, Grapes
The last few years have been exceptional for the start-up ecosystem. There is a surfeit of talent in the Indian marketplace and the start-up sector will continue to thrive in 2022 as well. In this rapidly changing world, Innovation is the key to survival for start-ups. In my belief, the continued development around crypto-currency, Fintech, E-commerce, Metaverse, and Pharma will be in the consumer’s mind. We can see a lot of developments in these sectors in the near future.
Nishant Behl | CEO & Founder, Expand My Business
Nishant Behl | CEO & Founder, Expand My Business
It has been a phenomenal ride for the start-ups in India, especially the emerging tech companies who are witnessing before themselves a new era of possibilities unfold. By the end of 2021, India has already become a home to around 81 unicorn companies of the world, of which 44 emerged to the status in a single year. The startup landscape seems to open up bigger and better possibilities in 2022. Buzzwords like crypto and blockchain are already resonating with the masses. An interesting scenario would be crypto transactions kicking off in the country.
Another interesting thing to look out for is the several IPOs set to happen all through the year. While there is still much to understand how the Metaverse can be related to startups, this virtual reality is set to transform the way a lot of the MSMEs and the business sector work from hereon. Among all the buzz, yet another concern is to create sustainable and more resilient operation systems in companies. All this sets the positive tone for the startup companies and ecosystem which are destined to become the next leaders of the changing world.
Vatsal Agarwal | Founder, The Baklava Box
Vatsal Agarwal – Founder, The Baklava-Box
The pandemic has been a sour spot not just for existing start-ups but also for upcoming ones. The WHO has predicted that 2022 will be a withering of the pandemic and it should be a great time for start-ups to pop up. Radical innovations in startups should be encouraged and the government has been giving impetus for entrepreneurship. Even in our business, brands are changing their outlook towards delivery. Since covid, the focus has been more on a delivery-based model than a traditional sit and eat or take away. That will continue in 2022 as well.
Varun Vashisthaa | Founder, HairVeda
Varun Vashistha | Founder, HairVeda
I feel that Indian Startups will try to create their mark in the global marketplace. Non-region-specific startups will definitely expand to the international audience once they have already captured the Indian market. Brands like ours can be hugely benefited from the international market since there is a massive demand and acceptance for ayurvedic products in countries like the USA, Mexico, etc. We all will see huge investments by the investor community in startups that have arrived with a purpose. Sustainable financing is the trend that will dominate the investment ecosystem for a long time. Crypto and Blockchains by startups will be seen from this year onwards and it will create a deep impact on the ecosystem.
Shriyans Bhandari | CEO & Co-Founder, Greensole
Shriyans Bhandari | CEO & Co-Founder, Greensole
2022 is the year for start-ups. While the pandemic keeps disturbing us time and again, panic has reduced. I think we will get used to the pandemic. It was a challenge earlier but it will not be anymore. Startups will get more room to grow. A lot of startups will fail during this time but the start-ups that will manage to pull through will flourish. New startups exploring new niches will also come about.
Kunal Patil | CEO & Co-Founder, WorkIndia
Kunal Patil | CEO & Co-Founder, WorkIndia
Services being offered by purely tech and tech-enabled companies played an important role during the crucial period of Covid-19. We expect 2022 to be another great year for the Indian Startup Ecosystem. Expect to see more companies catering to the smaller businesses and middle-income households
Entrepreneurship, collaboration, and innovation will be the hot topics in this new year since these are the three key pillars making the entire Indian startup ecosystem the dynamic and vibrant space that it is today. The lessons that all businesses learned over the past two years will be a crucial factor as startups navigate through the new normal. However, we believe that 2022 shows a great promise of being an exciting year for all startups.
Akshay Puljal | CEO, Quikish
Akshay Puljal | CEO, Quikish
Well, the first and foremost thing every startup needs to be prepared for is the continuation of the pandemic. We need to consider this in everything we do. In the F&B industry, you see the demand for clean food rising every day, and more people are leaning towards cooking in their kitchens than ordering from outside. We are glad that Quikish has got it covered already. We believe that Clean food and bringing. Convenience to home cook meals is the aspect which Quikish delivers without compromising on quality and flavours.
Shilpa Rathi | Founder, I Am Love
Shilpa Rathi | Founder, I AM Love
Start-ups are about solving our everyday problems. Start-ups usually succeed when they are able to solve problems that have existed for a long time but people have learned to overlook them. You have been living with the problems and one day you just get up and decide not to live with them anymore. These problems should have solutions to make our lives easier. I think that should always be a hot topic in any startup ecosystem. Apart from that, trying to get adequate funding is always going to be a hot topic. The launch and having a strong customer base and always be a hot topic. Establishing your brand and being able to track the brand engagement and following will always be a hot topic.
Farooq Adam | Co-Founder, Fynd
Farooq Adam | Co-Founder, Fynd
The lessons learned in the post-pandemic world will be crucial to growing your startup in 2022.
SaaS Products will continue to grow
SaaS will retain its throne & the market will welcome more cloud solutions with open arms. The surge in cloud software will continue to rise in 2022. More and more companies are making use of cloud software to manage data, productivity, and much more.
Mass acceptance of Deep-Tech
In the past 2 years, we have observed a radical emergence of deep tech. There will be a keen focus on implementing virtual technologies at the grassroots level. Indian startups raised $36 billion in 2021 to cope with the growing demand for digitization. As the pandemic stretches on, the technology efforts will start to gain more widespread acceptance. 2022 will see more innovation and increased tech adoption as extended reality makes its presence felt.
Hybrid Workforce
The reality is that the pandemic has been around for more than 2 years now, going to the office full time seems less and less likely. Organizations have to be open to the idea of hybrid work, where employees visit the office for a few days in the week/month/quarter and continue to work from home on day to day basis. People have also started to expect this flexibility from employers and it is important to listen to the pulse of the organization rather than imposing regulation.
Rasesh Seth | Founder, Nextyn
Rasesh Seth | Founder, Nextyn
We’re seeing a variety of industries that are disrupting traditional ecosystems across the globe. The fintech industry has particularly been of keen interest not only to us, but also to several clients that have been using our services. I believe 2022 is going to continue to fuel its growth, with higher adoption rates and exceedingly high digital payment transactions.
Another term that has been of keen startup interest is Automation. It’s not an independent industry, but the rapid rate at which literally everything is being automated, is frightfully exciting. I don’t think people are considering its long-term impact on the existing workforce, but it is surely making life easier for the vast majority. Right from daily tasks, to cars, to delivery or food. I think 2022 is going to be a year where we see a lot of our daily personal and professional tasks get automated. It’s an interesting space to watch, as its evolving at a monstrously rapid pace.
Conclusion
This is the age of Startups, they are making their presence known in every field and this is just the beginning. From new industries to more viable options regarding businesses. The Startup ecosystem is going to experience something even bigger and better in 2022.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by MedPlus.
There are millions of businesses in the world but not all of them carry equal importance. Some may be for entertainment, some for food, essentials, knowledge development, etc., but a basic requirement for running all the above businesses is our health. A place/business that helps us in taking good care of our health next to hospitals are the pharmacies. Carrying such importance, this industry has always seen growth. Now, by combining technology and healthcare needs, the pharmaceutical industry is enhancing itself to provide better and quick healthcare assistance to people.
MedPlus is one such pharmacy retailer offering multiple health services. They provide services like path labs, optical stores and physician consultation services, in addition to selling prescription medicines. MedPlus was established in 2006 by Madhukar Gangadi. Here, in this article, is the formation and growth of MedPlus along with its funding history, business and revenue models.
December 23, 2021 – Shares of MedPlus were listed on BSE and NSE on 23rd December. They were made available at a premium of 31 per cent. But the price ended at a gain of more than 40%, which is considered a big jump for MedPlus’s debut trade.
December 13, 2021 – The IPO subscription of MedPlus Healthcare Services opened on December 13. Though aggressive pricing has been followed by the company for its IPO, investors showed ample interest in the bidding. Almost 70% of the issue was subscribed on Day 1.
MedPlus Health Services IPO
MedPlus – About
MedPlus is an omnichannel pharmacy retailer offering healthcare services in India. The company sells medicines on prescriptions, FMCG products, nutritional supplements and many more. MedPlus also offers optical solutions and other medical consultation services in the country. It is based in Hyderabad and is the 2nd largest pharmacy chain in India, next to Apollo Pharmacy.
MedPlus, during its initial stages, operated under the name ‘Aushadi’. It was renamed ‘MedPlus’ after expanding its operation to over 48 retail stores. MedPlus Mart is the e-pharmacy store through which the company sells medicines online.
MedPlus – Industry
MedPlus belongs to the Pharmaceutical Industry. The pharmaceutical industry involves dealing with research, development, marketing and sales of medicines and drugs. They aim at preventing, protecting and curing the illness. The industry also deals with medical equipment and generic medications.
India’s pharma industry is huge. It is the largest supplier of generic medicines and ranks 3rd by overall production in the world. India meets the vaccine demand of the world by 50%, the generic medicine demand of the US by 40% and the UK by 25%.
MedPlus – Founders and Team
Madhukar Gangadi – MedPlus Founder
MedPlus was founded by Madhukar Gangadi in 2006 in Hyderabad. He has also served as the Chief Executive Officer of the company since its inception. Gangadi has an MBA degree from the Wharton School. He also earned a bachelor’s degree in medicine and surgery from the Sri Venkateshwara University. He used his experience in both healthcare and entrepreneurship to start MedPlus. The other core team members of MedPlus are:
Bhaskar Reddy Cherukupalli – COO (Retail stores)
Surendranath Mantena – COO (MedPlus Mart)
MedPlus – Mission and Vision
MedPlus Logo
MedPlus runs with a mission to turn itself as the customer’s first choice when it comes to medicines and healthcare. The company wants to understand the customer’s needs and exceed their expectations as much as possible. MedPlus has the vision to bring about a revolution in the healthcare industry in India.
MedPlus – Business and Revenue Model
MedPlus is an omnichannel platform that provides services through both retail stores and online platforms. The company increased its retail stores through franchises. MedPlus first chooses an area and studies its market, demographic needs and supply chain. Then it starts expanding its retail stores in and around the area by proper planning and implementation of strategies. Later, the company uses this growth and supply chain to expand its operations further.
MedPlus also operates its pharmacy business online through MedPlus Mart. This service was started in 2015 and was expanded across the country. MedPlus claims to be the first to start an omnichannel pharmacy in India. The company also entered the path labs and optical businesses in 2020. The revenue of MedPlus flows from the sale of medicines and other healthcare services offered by the company directly or through their franchisees across the country.
MedPlus – Challenges Faced
MedPlus faced severe challenges and criticisms at the time of establishing their online platform MedPlus Mart. The All India Organization of Chemists and Druggists (AIOCD) organized a nationwide strike against the company for starting e-pharmacies. They criticized that the chemists around the country will be severely affected by this MedPlus’s initiative. Then MedPlus made their sales policy explicit and clarified that they are complying with every aspect of the Drug Act.
MedPlus – Funding and Investors
MedPlus managed to raise a sum of $317.7 million through 7 rounds of funding. A total of 6 investors have invested in the company so far. Here is the company’s list of fundings:
Date
Round
Money
Investors
February 11, 2021
Private Equity Round
$13.5 million
Warburg Pincus, PremjiInvest
April 1, 2019
Series C
–
PremjiInvest
January 2, 2018
Debt Financing
$117.7 million
Goldman Sachs
December 15, 2017
Series C
$1.1 million
–
November 10, 2014
Series C
$89.9 million
Mount Kellett Capital Management
March 14, 2011
Private Equity Round
$90 million
TVS Capital Funds, Mount Kellett Capital Management
March 22, 2007
Private Equity Round
$3.1 million
Peepul Capital LLC
MedPlus – Growth
Starting its operations in 2006, MedPlus has seen enormous growth in about one and half decades. Today, the company has widened its business to over 2100 pharmacies across 7 Indian states. It also adapted to the technological advancements and established an online platform in 2015 to ease and widen its sales to customers. MedPlus has now issued its IPO thus aiming to enlarge its operations to every corner of the country in the future.
MedPlus also had consistent revenue growth over the years. The company’s CAGR growth is expected to grow 25% between the financial year 2020 and 2025. The market share of this omnichannel entity is 22% as of 2021. Similarly, the company reported an increase in revenue and profit for 2021, which was severely affected in 2020 due to the pandemic. At the end of the third quarter of 2021, MedPlus had revenue of ₹1890.9 crores and a profit of ₹66.36 crores.
MedPlus – Competitors
MedPlus has earned quite a good competition all through its operation span of over 16 years. Few of them, like Apollo, are omnichannel competitors. In fact, Apollo stands to be the largest pharmacy retail chain in India. In addition to it, few other companies, which show promising growth and worthy competition to MedPlus, have emerged. Here are some of them:
MedPlus launched its Initial Public Offering in the name of MedPlus Health Services by mid-December 2021. The company is expected to be valued high in the near future. It is also planning for potential financial growth in the long term. MedPlus has decided to use the proceeds from IPO for meeting the future working capital requirements of the company. The majority of the funds are expected to be used for developing Optival Health Solutions. MedPlus is strategically planning every step to bridge the gap with the competitor ahead. The CEO Madhukar Gangadi confidently said that the MedPlus will overtake Apollo within the next two and half years.
MedPlus – FAQs
What is MedPlus?
MedPlus is an omnichannel pharmacy retailer offering healthcare services in India.
Who is the founder of MedPlus?
Madhukar Gangadi founded MedPlus in 2006. He is the CEO of the company.
Who are the top competitors of MedPlus?
Some of the top competitors of MedPlus are:
PharmEasy
Apollo pharmacies
Netmeds
1mg
MedLife
How many retail stores does MedPlus have in India?
MedPlus has over 2100 stores in the country as of March 31, 2021.
